Abstract
Objective Highly comparative time series analysis (HCTSA) is a novel approach involving massive feature extraction using publicly available code from many disciplines. The Prematurity-Related Ventilatory Control (Pre-Vent) observational multicenter prospective study collected bedside monitor data from > 700 extremely preterm infants to identify physiologic features that predict respiratory outcomes. We calculated a subset of 33 HCTSA features on > 7M 10-minute windows of oxygen saturation (SPO2) and heart rate (HR) from the Pre-Vent cohort to quantify predictive performance. This subset included representatives previously identified using unsupervised clustering on > 3500 HCTSA algorithms. Performance of each feature was measured by individual area under the receiver operating curve (AUC) at various days of life and binary respiratory outcomes. These were compared to optimal PreVent physiologic predictor IH90 DPE, the duration per event of intermittent hypoxemia events with threshold of 90%.
Main Results The top HCTSA features were from a cluster of algorithms associated with the autocorrelation of SPO2 time series and identified low frequency patterns of desaturation as high risk. These features had comparable performance to and were highly correlated with IH90 DPE but perhaps measure the physiologic status of an infant in a more robust way that warrants further investigation. The top HR HCTSA features were symbolic transformation measures that had previously been identified as strong predictors of neonatal mortality. HR metrics were only important predictors at early days of life which was likely due to the larger proportion of infants whose outcome was death by any cause. A simple HCTSA model using 3 top features outperformed IH90 DPE at day of life 7 (.778 versus .729) but was essentially equivalent at day of life 28 (.849 versus .850). These results validated the utility of a representative HCTSA approach but also provides additional evidence supporting IH90 DPE as an optimal predictor of respiratory outcomes.
Competing Interest Statement
Moorman is a consultant for Nihon Kohden Digital Health Solutions; proceeds are donated to the University of Virginia. Lake and Moorman own stock in Medical Predictive Sciences Corporation.
Funding Statement
The study was funded as part of an NIH U01 cooperative agreement: University of Virginia (NCT03174301): U01 HL133708, HL133708-05S1; Case Western Reserve University: U01 HL133643, The Gerber Foundation; Northwestern University: U01 HL133704; University of Alabama at Birmingham: U01 HL133536; University of Miami: U01 HL133689; Washington University: U01 HL133700.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was obtained at all sites - Northwestern University, Case Western University, the University of Alabama-Birmingham, Washington University - St Louis, and the University of Miami. The University of Virginia served as Leadership and Data Coordination Center (LDCC). Waiver of consent was approved by the LDCC IRB and 3 of 5 CRC IRBs, while 2 CRC sites obtained consent. Oversight was provided by an observational safety monitoring board, appointed by the National Heart, Lung, Blood Institute (NHLBI).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets are available from the corresponding author upon reasonable request.
